

1 **Title:** Integrative genomics analysis implicates decreased *FGD6* expression underlying risk of intracranial
2 aneurysm rupture

3

4 **Authors:** Andrew T. Hale MD, PhD,¹ Jing He MS,² and Jesse Jones MD¹

5

6 **Affiliations:** ¹Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL;

7 ²Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN.

8

9 **Corresponding Author:**

10 Andrew T Hale, MD, PhD

11 Department of Neurosurgery

12 University of Alabama at Birmingham

13 FOT Suite 1060, 1720 2nd Ave S.

14 Birmingham, AL 35294

15 Andrewthale20@gmail.com

16

17 The authors have declared that no conflict of interest exists.

18

19

20

21 **Abstract**

22 **Background:** The genetic determinants and mechanisms underlying intracranial aneurysm rupture (rIA)
23 are largely unknown. Given the ~50% mortality rate of rIA, approaches to identify patients at high-risk will
24 inform screening, diagnostic, and preventative measures.

25 **Objective:** Our goal was to identify and characterize the genetic basis of rIA.

26 **Methods:** We perform a genome-wide association study (GWAS) use functional genomics approaches to
27 identify and characterize rIA-associated loci and genes. We perform a meta-analysis across 24 published
28 GWAS of rIA. Single nucleotide polymorphisms (SNP), gene-burden analysis, and functional genomics
29 identify and characterize genetic risk factors for rIA.

30 **Results:** Our cohort contains 84,353 individuals (7,843 rIA cases and 76,510 controls). We identify 5
31 independent genetic loci reaching genome-wide significance ($p < 5.0 \times 10^{-8}$) for rIA including rs12310399
32 (*FGD6*, OR=1.16), which to our knowledge, has not been implicated in prior GWAS of rIA. We then
33 quantified gene-level mutation-burden across ~20,000 genes, and only *FGD6* (containing 21 rIA-
34 associated SNPs) reached transcriptome-wide significance. Expression quantitative trait loci (eQTL)
35 mapping indicates that rs12310399 causes decreased *FGD6* gene expression in arterial tissue. Next, we
36 utilized publicly available single-cell RNA sequencing of normal human cerebrovascular cells obtained
37 during resection surgery and identify high expression of *FGD6* in 1 of 3 arterial lineages but absent in
38 perivascular cells. These data suggest how alterations in *FGD6* may confer risk to rIA.

39 **Conclusion:** We identify and characterize a previously unknown risk loci for rIA containing *FGD6*.
40 Elucidation of high-risk genetic loci may instruct population-genetic screening and clinical-genetic testing
41 strategies to identify patients predisposed to rIA.

42

43 **Funding:** No funding sources were used for the material presented herein.

44 **Introduction**

45 Intracranial aneurysms (IA) are abnormal dilations of cerebral arteries that occur in response to
46 vessel wall dysfunction. Spontaneous rupture of an IA (rIA) causes severe neurological injury and
47 death.^{1,2} IA is estimated to affect around 5% of the world's population with lifetime rupture-risk of ~25%.³
48 However, the mortality of rIA is ~50%.⁴ While many rIA risk-factors including family history, female
49 gender, aneurysm location/size, cigarette smoking, and hypertension have been elucidated in large
50 epidemiological studies,⁵ these factors are largely non-specific. Thus, personalized genetic approaches to
51 1) identify patients with IA, and 2) predict which patients with IA are most likely to rupture are needed.

52 Elucidating causal genetic factors associated with rIA has direct implications for disease
53 prevention, diagnosis, and treatment. While rare inherited causes of IA have been described,⁶ these
54 patients comprise the minority of total IA disease burden.⁷ Family history of rIA in first-degree relatives,
55 even in the absence of a known IA-associated genetic syndrome, increases one's risk of being diagnosed
56 with rIA by nearly four-fold.⁸ Thus, a strong genetic component is thought to underlie IA,⁹ and unbiased,
57 genome-wide approaches to understand the germline-genetic determinants of IA formation and rupture
58 are critical to understanding IA pathophysiology and quantification of rupture risk. Since one's genetic
59 information in large part does not change over a lifetime (excluding somatic mutations), elucidating the
60 genetic architecture of rIA can inform screening, detection, and treatment (for patients at the highest risk)
61 strategies. In this study, we systematically delineate the genetic determinants of rIA using convergent
62 human-genetic and functional genomics approaches.

63

64 **Methods**

65 *Genome wide association study analysis*

66 Genetic data were obtained using the Cerebrovascular Disease Knowledge Portal
67 (cerebrovascularportal.org).¹⁰ GWAS was performed as previously described.^{11,12} Whole-genome
68 genotyping was performed using Illumina HumanOmniExpressExome BeadChip.¹⁰ Imputation was
69 performed using the 1000 genome reference panel,¹³ Haplotype Reference Consortium, or the UK10K
70 using IMPUTE4 software.¹⁴ Meta-analysis was performed using inverse-variance method and Cochran's
71 Q test (to estimate heterogeneity) with METAL.^{15,16} Age, sex, and the first twenty principal components

72 were included as covariates in logistic regression models to identify IA-associated SNPs as previously
73 described.¹⁷ Threshold for genome-wide significance was defined after Bonferroni correction for the total
74 number of SNPs tested ($p \leq 5.0 \times 10^{-8}$). Our cohort contained patients of both European and East-Asian
75 ancestry. Assuming a disease prevalence for IA of 5%,¹⁸ rs73392700 allele frequency of 0.12 (the most
76 statistically-significant SNP identified in our GWAS), and genotype relative risk of 1.5, our study is
77 appropriately powered to 1.0 (GAS power calculator from the University of Michigan, csg.sph.umich.edu).
78 STREGA reporting guidelines for genetic association studies were followed.¹⁹

79

80 *Functional genomics analysis*

81 The latest data release of GTEx (version 8) was used.²⁰ The GTEx portal (gtexportal.org) was
82 used for data visualization. Expression quantitative trait loci (eQTL) analysis, which estimates the
83 functional effect of a SNP/loci on neighboring gene expression, was performed as previously
84 described.^{11,20} Splicing quantitative trait loci (sQTL) was used to determine the potential impact of a SNP
85 on alternative splicing.²¹ In addition, we used Haploreg,²² a functional genomics tool to explore the
86 function of variants in non-coding regions of the genome. Haploreg combines data from the 1000
87 genomes project, Roadmap Epigenomics, and ENCODE projects to estimate the effect of SNPs on
88 functions such as chromatin state, protein-binding, and gene-expression. Data visualization was
89 performed using gtexportal.org. Finally, we utilized single-cell RNA sequencing analysis of adult human
90 brain endothelial and perivascular cells obtained from normal brain cortex biopsies obtained as previously
91 described.²³

92

93 **Results**

94 Our cohort contained 84,353 individuals (7,843 rIA cases and 76,510 controls) across 24
95 published GWAS.¹⁰ Our GWAS identified 5 independent genetic loci reaching genome-wide significance
96 for rIA (Figure 1A): rs73392700 (*CDKN2B*, $p=4.84 \times 10^{-17}$, OR=1.12), rs6841581 (*EDNRA*, $p=3.52 \times 10^{-14}$,
97 OR=0.77), rs11661542 (*RBBP8*, $p=3.18 \times 10^{-13}$, OR=0.84), rs62516550 (*RP1*, $p=2.94 \times 10^{-11}$, OR=1.20),
98 and rs12310399 (*FGD6*, $p=3.19 \times 10^{-10}$, OR=1.16). The *FGD6* loci, to our knowledge, has not been
99 implicated in prior GWAS of rIA. We confirmed that population stratification and genomic control was

100 adequately achieved (i.e., no early deviation of p-values from expected, lambda statistic 1.048) by
101 generating a quantile-quantile plot (Figure 1B).

102 Consistent with GWAS studies of complex and polygenic diseases, the vast majority of identified
103 genetic risk factors are located in non-coding regions of the genome, making causal inference of disease
104 mechanisms challenging.²⁴ To overcome these challenges and delineate the functional consequences of
105 rIA-associated single-nucleotide polymorphisms (SNPs), we analyzed the summative contribution of rIA
106 associated SNPs across ~20,000 individual genes using gene-burden analysis.²⁵ Determining gene-
107 based, rather than variant-based, associations with rIA will facilitate ease of biologic interpretation and
108 design/interpretation of mechanistic studies. Across all rIA-associated SNPs and genes tested, 958 genes
109 were associated with rIA ($p < 0.05$). However, after multiple-testing correction, only *FGD6* (harboring 21
110 rIA-associated SNPs) reached transcriptome-wide significance.

111 To visualize the *FGD6* locus for rIA-associated SNPs, we present a LocusZoom plot (Figure 2).
112 These data demonstrate the extent to which multiple variants in this locus, alone and in concert through
113 linkage disequilibrium (LD), contribute to rIA risk. To delineate the effect of rIA-associated SNPs on gene
114 expression, we present eQTL mapping across 49 tissue types using the Genotype-Tissue Expression
115 Project (GTEx) portal²⁶ and demonstrate that the most significant rIA-associated SNP in the *FGD6* loci
116 (rs12310399) causes decreased *FGD6* gene expression most-significantly in arterial tissue (Figure 3). In
117 addition, rs12310399 overlaps splicing QTLs for vezatin (*VEZT*, $p < 8.20 \times 10^{-9}$, skeletal muscle,
118 gtexportal.org), a transmembrane protein in the adherens junction that binds to myosin VIIA²⁷ and NADH
119 ubiquinone oxidoreductase subunit A12 (*NDUFA12*, $p < 8.20 \times 10^{-9}$, skeletal muscle, gtexportal.org), a
120 gene previously implicated in IA biology.²⁸ These data provide additional support for this locus and
121 suggests that multiple mechanisms are likely contributing to rIA risk.

122 While identification of new rIA-associated genes is important, it is the function of that gene in
123 relevant tissues/cells that will expand our pathophysiologic understanding of IA formation and rupture. To
124 further delineate the cellular origin and functional consequences of *FGD6* expression in the
125 cerebrovascular system, we utilize scRNA-seq data derived from normal adult human brain endothelial
126 and perivascular cells as previously described.²³ We find that *FGD6* is highly expressed in 1 of 3 arterial
127 lineages, venules, and veins but *FGD6* expression is largely undetectable across 12 perivascular cell

128 lineages (Figure 5A-B). These findings will facilitate additional mechanistic studies aimed at
129 understanding the molecular basis of *FGD6* dysfunction underlying rIA.

130

131 **Discussion**

132 We identify 5 independent genetic loci reaching genome-wide significance for rIA, including a
133 novel locus containing *FGD6* not previously implicated in rIA biology. Gene-burden analysis provides
134 convergent evidence supporting the *FGD6* gene in rIA risk. Functional characterization indicates that
135 genetic variation in *FGD6* loci contributes to rIA risk by decreasing *FGD6* gene expression in arterial
136 tissue. Utilization of single-cell RNA sequencing analysis of human brain endothelial and perivascular
137 cells²³ characterizes *FGD6* expression across rIA-relevant neurovascular cell types where alterations in
138 *FGD6* expression may alter cell identity and function. These data will inform detailed mechanistic analysis
139 of *FGD6* in rIA biology and perhaps even treatment strategies. These data suggest that variable
140 expressivity of *FDG6* causes a range of clinical features from Mendelian disease to sporadic rIA.

141 *FGD6* (FYVE RhoGef and Ph domain containing protein 6) is a RhoGTPase that activates
142 *CDC42*, a cell cycle-associated gene, and *FGD6* has been shown to play a role in regulating
143 angiogenesis and actin cytoskeleton rearrangement,²⁹ functions consistent with rIA. Functional analysis
144 indicates that *FGD6* regulates angiogenesis and actin cytoskeleton rearrangement.²⁹ Thus, it is
145 reasonable to posit that *FGD6*-dependent alterations in blood vessel integrity and/or formation may, at
146 least in part, contribute to rIA. *FGD6* mediated genetic susceptibility coupled with clinical risk factors
147 (hypertension, smoking, etc.) converge to contribute summative risk for rIA. Whole-gene deletion or
148 introduction of *FGD6* disease-causing mutations disrupts endothelial cell network formation which could
149 be rescued by introduction of the wild-type gene product.

150 While the focus of this manuscript is on identification and characterization of the *FGD6* loci,
151 multiple genetic loci are contributing to rIA (Figure 1). Although the magnitude of effect is relatively small
152 for the lead SNP in the *FGD6* loci (OR= 1.16), the clinical consequences of genetic-testing underlying rIA
153 are more likely to be representing through assessment of polygenic risk score (PRS).³⁰ The weighted
154 contribution of multiple loci through creation of a PRS will improve our understanding of rIA genetic
155 architecture.³¹ In addition, combining PRS with important clinical and radiologic features of patients with

156 rIA will improve translational of these genetic findings to clinical care. As our ability to acquire, analyze,
157 and interpret genetic information improves, we surmise that translating genetic information into clinical
158 practice will become streamlined.

159 Our cohort is the largest studies of rIA to date, but additional genetic data from diverse
160 populations will increase power to detect additional risk loci and improve applicability of the genetic
161 information across diverse populations. One limitation of array based GWAS is our relative inability to
162 include rare variants, although detailed analysis of IA rare variants has been performed elsewhere.^{32,33}
163 Multiple studies of rIA have implicated common variants underling IA risk.^{10,28,34-39} Thus, it is likely that
164 both common and rare variants in both coding and non-coding regions confer risk to IA, alone and in
165 concert. In addition, recent studies suggest that somatic mutations may play a role in IA pathology,^{40,41}
166 which we did not assess herein, but may play a significant role in rIA pathogenesis. Analysis of lesional
167 tissue acquired through advances in endoluminal biopsy will promote our understanding of somatic
168 contribution to rIA biology.⁴² Integration of clinical and aneurysm-specific factors (size, location, etc.) will
169 enable personalized medicine approaches to IA treatment and expand the clinician's armamentarium.

170 Here we perform a large genetic study of rIA and identify and characterize a previously unknown
171 risk locus for rIA containing *FGD6*. Since the genetic contribution to rIA risk does not change (excluding
172 somatic mutations), approaches to quantify genetic risk of rIA may be extremely valuable for clinical
173 treatment. Integration of clinical and radiologic IA factors with genetic data will further improve our ability
174 to comprehensively evaluate rIA risk. Understanding the genetic determinants of rIA may inform gene-
175 based therapies aimed at IA remodeling or obliteration. Strategies to incorporate genetic information into
176 clinical care will inform personalized medicine approaches to manage IA.

177

178 **Acknowledgements**

179 The authors would like to thank the creators of the Cerebrovascular Disease Knowledge Portal. In
180 addition, we would like to thank GTEx which is supported by the Common Fund of the Office of the
181 Director of the NIH, the National Cancer Institute (NCI), the National Human Genome Research Institute
182 (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Drug Abuse
183 (NIDA), the National Institute of Mental Health (NIMH), and the National Institute of Neurological


184 Disorders and Stroke (NINDS). We would also like to thank Haploreg (Broad Institute) - which also utilizes
185 Roadmap Epigenomics, 1000 Genomes Project, and ENCODE data - for use of their resource.
186

References


- 187
188
189 1. Lawton MT, Vates GE. Subarachnoid Hemorrhage. *N Engl J Med.* 2017;377(3):257-266.
- 190 2. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. *Lancet.*
191 2017;389(10069):655-666.
- 192 3. Korja M, Kaprio J. Controversies in epidemiology of intracranial aneurysms and SAH. *Nat Rev*
193 *Neurol.* 2016;12(1):50-55.
- 194 4. Schievink WI. Intracranial Aneurysms. *New England Journal of Medicine.* 1997;336(1):28-40.
- 195 5. Teunissen LL, Rinkel GJ, Algra A, van Gijn J. Risk factors for subarachnoid hemorrhage: a
196 systematic review. *Stroke.* 1996;27(3):544-549.
- 197 6. Ilinca A, Samuelsson S, Piccinelli P, Soller M, Kristoffersson U, Lindgren AG. A stroke gene panel
198 for whole-exome sequencing. *European journal of human genetics : EJHG.* 2018.
- 199 7. Zhou S, Dion PA, Rouleau GA. Genetics of Intracranial Aneurysms. *Stroke.* 2018;49(3):780-787.
- 200 8. Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms,
201 with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-
202 analysis. *The Lancet Neurology.* 2011;10(7):626-636.
- 203 9. Kleinloog R, van 't Hof FN, Wolters FJ, et al. The association between genetic risk factors and the
204 size of intracranial aneurysms at time of rupture. *Neurosurgery.* 2013;73(4):705-708.
- 205 10. Bakker MK, van der Spek RAA, van Rheenen W, et al. Genome-wide association study of
206 intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors. *Nat*
207 *Genet.* 2020;52(12):1303-1313.
- 208 11. Hale AT, Akinnusotu O, He J, et al. Genome-Wide Association Study Identifies Genetic Risk
209 Factors for Spastic Cerebral Palsy. *Neurosurgery.* 2021;89(3):435-442.
- 210 12. Hale AT, Bastarache L, Morales DM, Wellons JC, 3rd, Limbrick DD, Jr., Gamazon ER. Multi-omic
211 analysis elucidates the genetic basis of hydrocephalus. *Cell Rep.* 2021;35(5):109085.
- 212 13. Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample Resource
213 (IGSR) collection of open human genomic variation resources. *Nucleic Acids Res.*
214 2020;48(D1):D941-d947.
- 215 14. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and
216 genomic data. *Nature.* 2018;562(7726):203-209.
- 217 15. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association
218 scans. *Bioinformatics.* 2010;26(17):2190-2191.
- 219 16. Hale AT, He J, Akinnusotu O, et al. Genome-wide association study reveals genetic risk factors
220 for trigeminal neuralgia. *medRxiv.* 2021:2021.2002.2008.21251349.
- 221 17. Hale AT, Zhou D, Sale RL, et al. The genetic architecture of human infectious diseases and
222 pathogen-induced cellular phenotypes. *medRxiv.* 2021:2020.2007.2019.20157404.
- 223 18. Caranci F, Briganti F, Cirillo L, Leonardi M, Muto M. Epidemiology and genetics of intracranial
224 aneurysms. *Eur J Radiol.* 2013;82(10):1598-1605.

- 225 19. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association
226 Studies (STREGA): an extension of the STROBE statement. *PLoS medicine*. 2009;6(2):e22.
- 227 20. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science (New
228 York, NY)*. 2020;369(6509):1318-1330.
- 229 21. Li YI, Knowles DA, Humphrey J, et al. Annotation-free quantification of RNA splicing using
230 LeafCutter. *Nature genetics*. 2018;50(1):151-158.
- 231 22. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and
232 regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*.
233 2012;40(Database issue):D930-934.
- 234 23. Winkler EA, Kim CN, Ross JM, et al. A single-cell atlas of the normal and malformed human brain
235 vasculature. *Science (New York, NY)*. 2022:eabi7377.
- 236 24. Tak YG, Farnham PJ. Making sense of GWAS: using epigenomics and genome engineering to
237 understand the functional relevance of SNPs in non-coding regions of the human genome.
238 *Epigenetics Chromatin*. 2015;8:57.
- 239 25. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of
240 GWAS data. *PLoS Comput Biol*. 2015;11(4):e1004219.
- 241 26. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene
242 regulation in humans. *Science (New York, NY)*. 2015;348(6235):648-660.
- 243 27. Guo X, Jing C, Li L, et al. Down-regulation of VEZT gene expression in human gastric cancer
244 involves promoter methylation and miR-43c. *Biochemical and biophysical research
245 communications*. 2011;404(2):622-627.
- 246 28. Yasuno K, Bakırcioğlu M, Low SK, et al. Common variant near the endothelin receptor type A
247 (EDNRA) gene is associated with intracranial aneurysm risk. *Proc Natl Acad Sci U S A*.
248 2011;108(49):19707-19712.
- 249 29. Huang L, Zhang H, Cheng CY, et al. A missense variant in FGD6 confers increased risk of
250 polypoidal choroidal vasculopathy. *Nat Genet*. 2016;48(6):640-647.
- 251 30. GWAS to the people. *Nat Med*. 2018;24(10):1483.
- 252 31. Dudbridge F. Power and predictive accuracy of polygenic risk scores. *PLoS Genet*.
253 2013;9(3):e1003348.
- 254 32. Kurki MI, Gaál EI, Kettunen J, et al. High risk population isolate reveals low frequency variants
255 predisposing to intracranial aneurysms. *PLoS Genet*. 2014;10(1):e1004134.
- 256 33. Barak T, Ristori E, Ercan-Sencicek AG, et al. PPIL4 is essential for brain angiogenesis and
257 implicated in intracranial aneurysms in humans. *Nat Med*. 2021;27(12):2165-2175.
- 258 34. Bilguvar K, Yasuno K, Niemelä M, et al. Susceptibility loci for intracranial aneurysm in European
259 and Japanese populations. *Nat Genet*. 2008;40(12):1472-1477.
- 260 35. Yasuno K, Bilguvar K, Bijlenga P, et al. Genome-wide association study of intracranial aneurysm
261 identifies three new risk loci. *Nat Genet*. 2010;42(5):420-425.

- 262 36. Foroud T, Koller DL, Lai D, et al. Genome-wide association study of intracranial aneurysms
263 confirms role of Anril and SOX17 in disease risk. *Stroke*. 2012;43(11):2846-2852.
- 264 37. Low SK, Takahashi A, Cha PC, et al. Genome-wide association study for intracranial aneurysm in
265 the Japanese population identifies three candidate susceptible loci and a functional genetic
266 variant at EDNRA. *Human molecular genetics*. 2012;21(9):2102-2110.
- 267 38. Foroud T, Lai D, Koller D, et al. Genome-wide association study of intracranial aneurysm
268 identifies a new association on chromosome 7. *Stroke*. 2014;45(11):3194-3199.
- 269 39. Laarman MD, Vermunt MW, Kleinloog R, et al. Intracranial Aneurysm-Associated Single-
270 Nucleotide Polymorphisms Alter Regulatory DNA in the Human Circle of Willis. *Stroke*.
271 2018;49(2):447-453.
- 272 40. Chenbhanich J, Hu Y, Hetts S, et al. Segmental overgrowth and aneurysms due to mosaic
273 PDGFRB p.(Tyr562Cys). *Am J Med Genet A*. 2021;185(5):1430-1436.
- 274 41. Karasozen Y, Osbun JW, Parada CA, et al. Somatic PDGFRB Activating Variants in Fusiform
275 Cerebral Aneurysms. *Am J Hum Genet*. 2019;104(5):968-976.
- 276 42. Winkler EA, Wu D, Gil E, et al. Endoluminal Biopsy for Molecular Profiling of Human Brain
277 Vascular Malformations. *Neurology*. 2022.
- 278 43. Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of
279 genome-wide association studies. *Am J Hum Genet*. 2011;88(5):586-598.
- 280 44. Han B, Eskin E. Interpreting meta-analyses of genome-wide association studies. *PLoS Genet*.
281 2012;8(3):e1002555.
282
- 283




285 **Figure 1.** Genome-wide association study (GWAS) of ruptured intracranial aneurysms (rIA). (A)
286 Manhattan plot of our rIA GWAS containing 84,353 individuals (7,843 rIA cases and 76,510 controls) and
287 identify 5 independent genetic loci reaching genome-wide significance ($p < 5.0 \times 10^{-8}$) for rIA: rs73392700
288 (*CDKN2B*, OR=1.12), rs6841581 (*EDNRA*, OR=0.77), rs11661542 (*RBBP8*, OR=0.84), rs62516550
289 (*RP1*, OR=1.20), and rs12310399 (*FDG6*, OR=1.16). The horizontal red line delineates the threshold for
290 genome-wide significance ($p = 5.0 \times 10^{-8}$). (B) Quantile-Quantile (Q-Q) plot demonstrating adequate
291 genomic control for population stratification (Lambda statistic 1.048). These data are visualized using the
292 cd.hugemap.org.
293



294
295
296

Figure 2. LocusZoom plot after fine-mapping of rIA-associated SNPs in the *FGD6* locus.



297

298 **Figure 3.** Expression quantitative trait loci (eQTL) analysis of the *FGD6* locus sentinel variant


299 (rs12310399) across 49 tissues in GTEx. NES = normalized enrichment score. The m-value is the

300 posterior probability from MetaSoft which is the probability than an eQTL effect exists in the tested cross-


301 tissue analysis^{43,44}. A m-value < 0.01 is highly suggestive that an eQTL effect does not exist, whereas a

302 m-value > 0.9 is highly predictive of an eQTL effect. Data were visualized using gtexportal.org.

303



305 **Figure 4.** Functional mapping of the *FGD6* locus in arterial tissue. Expression quantitative trait loci
306 (eQTL), splicing quantitative trait loci (sQTL), and linkage disequilibrium (LD) mapping of the *FGD6* locus.
307 Abbreviations are as follows: Transcription end site (TES), Transcription start site (TSS), Aortic artery
308 (ARTORT), Tibial artery (ARTTBL). Data were visualized using gtexportal.org.
309
310



311
312 **Figure 5.** Single-cell RNA sequencing (scRNA-seq) analysis of *FGD6* across adult human brain (A)
313 endothelial and (B) perivascular cells obtained from normal resected brain tissue. Endothelial cells were
314 characterized into 3 arterial lineages (Art1-3), capillary (cap), venous, and venule cell-lineages. Blue dots
315 indicate undetectable expression of *FGD6*, and increasingly dark shades of orange indicate higher
316 expression of *FGD6*. Perivascular cells were partitioned into 7 smooth muscle (SMC1-7), 2 fibroblast
317 (FB), 2 fibromyocyte (FbM1-2), and 1 pericyte (PC) lineage. Green dots indicate undetectable expression
318 of *FGD6* and red dots indicate higher expression of *FGD6*. UMAP data visualization and gene-
319 expression markers for cell populations was performed using the UCSC Cell Browser.